Clinical Trial Update: A Study to Compare Sacituzumab Tirumotecan (MK-2870) Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants With Recurrent or Metastatic Cervical Cancer (MK-2870-020/TroFuse-020/Gog-3101/ENGOT-cx20) [Phase 3]

View source ↗

Summary

A Phase 3 trial is evaluating sacituzumab tirumotecan as second-line monotherapy for recurrent or metastatic cervical cancer, compared with physician's choice t…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cervical Cancer

Drugs mentioned

• Sacituzumab Tirumotecan (Sacituzumab govitecan)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Cervical Cancer | Phase 3 | Status: RECRUITING